Boehringer and EFSD show support for innovative diabetes research

Three diabetes researchers have become the first beneficiaries of new research funding by Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD).
The pharmaceutical company and the EFSD have announced that a total of 2.5 million Euros (£2.15 million) will be provided to three award-winning projects led by Stefan Amisten of King’s College London, Hiddo Heerspink of the University Medical Center Groningen and Markus van der Giet of the Charity University Berlin.
The funding is part of the EFSD/Boehringer Ingelheim European Diabetes Research Programmes, which are designed to support revolutionary research into the disease.
“These grants reflect our continued commitment to supporting medical innovation in diabetes research, a disease which affects over 370 million people worldwide,” said Professor Klaus Dugin, corporate senior vice-president for medicine at Boehringer Ingelheim.
Research areas in particular that Boehringer is hoping to encourage are mechanisms relating renal dysfunction to cardiovascular disease in type 2 diabetes, and regulating the secretion and/or function of non-insulin peptides from the endocrine pancreas.
Earlier this week, the drugmaker teamed up with US digital health management specialist Healthrageous and pharmaceutical services provider United BioSource (UBC) to assess the potential health benefits of a new digital self-management programme for adult patients with type 2 diabetes.
The online and mobile-based programme aims to evaluate the effect of a digital diabetes platform on medical and pharmaceutical costs, clinical care and patient behaviour.